Protalix BioTherapeutics, Inc.
New York Stock Exchange ArcaRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Protalix BioTherapeutics, Inc. (NYSE American: PLX) is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based ProCellEx expression system. The company offers taliglucerase alfa (marketed as Elelyso for Gaucher disease, licensed to Pfizer Inc. worldwide excluding Brazil where it retains rights under BioManguinhos alfataliglicerase), pegunigalsidase alfa (marketed as Elfabrio for Fabry disease, partnered with Chiesi Farmaceutici S.p.A. for global development and commercialization following FDA and EMA approvals in May 2023); its pipeline includes PRX-115, a recombinant PEGylated uricase for uncontrolled gout advancing toward Phase 2 initiation in the second half of 2025, PRX-119, a long-acting DNase I for neutrophil extracellular traps-related diseases, and other candidates targeting rare diseases such as respiratory conditions. Founded in 1993 and headquartered in Carmiel, Israel, with additional facilities referenced in Hackensack, New Jersey, Protalix operates primarily in the United States, Brazil, Europe, Israel, Australia, Canada, Russia, and Turkey, serving patients with rare lysosomal storage disorders and related conditions through partnerships with Pfizer, Chiesi Global Rare Diseases, and Fiocruz. Recent developments include a 50% revenue increase from goods sales in the first half of 2025 versus 2024, completion of Phase 1 for PRX-115 with first Phase 2 patient enrollment planned for Q4 2025, achievement of debt-free status via repayment of all convertible notes, EMA validation of a pegunigalsidase alfa dosing variation submission with Chiesi, and 24% year-to-date revenue growth to $43.6 million through Q3 2025 driven by sales of Elfabrio, Elelyso, and Uplyso despite quarterly fluctuations from partner inventory timing.
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results
Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026
Protalix Revenue Miss Overshadowed By Milestone-Backed 2026 Guidance
Americans are richer in shares, Europeans in bricks – and that matters now
Tesla targets December 2026 for next-generation AI6 chip tape-out
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025
Pennon shares rise despite profit warning as storm costs and sewage penalties bite
Physiomics shares fall 27% after discounted share placing
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen
Ticketmaster owner Live Nation reaches antitrust settlement with US Justice Department
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
Reviewing Protalix BioTherapeutics (NYSE:PLX) & JATT Acquisition (NYSE:JATT)
Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial Launch
A March Decision That Could Change Protalix BioTherapeutics Outlook
Protalix wins EU panel backing for expanded dosing of Fabry disease drug